US20080025989A1 - Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders - Google Patents

Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders Download PDF

Info

Publication number
US20080025989A1
US20080025989A1 US11/735,376 US73537607A US2008025989A1 US 20080025989 A1 US20080025989 A1 US 20080025989A1 US 73537607 A US73537607 A US 73537607A US 2008025989 A1 US2008025989 A1 US 2008025989A1
Authority
US
United States
Prior art keywords
antibody
seq
amino acid
cells
forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/735,376
Inventor
Che-Leung Law
Julie McEarchern
Jonathan Drachman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US44905503P priority Critical
Priority to US10/546,304 priority patent/US7662387B2/en
Priority to PCT/US2004/005247 priority patent/WO2004073656A2/en
Priority to US79212706P priority
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Priority to US11/735,376 priority patent/US20080025989A1/en
Assigned to SEATTLE GENETICS, INC. reassignment SEATTLE GENETICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DRACHMAN, JONATHAN G., LAW, CHE-LEUNG, MCEARCHERN, JULIE
Publication of US20080025989A1 publication Critical patent/US20080025989A1/en
Abandoned legal-status Critical Current

Links